4.1.36 Mandatory Disclosures

Consistent with 2 CFR Part 200.113, NIH applicants, recipients, or subrecipients must promptly disclose in writing to the NIH awarding IC The NIH organizational component responsible for a particular grant program or set of activities. The terms "NIH IC," or "awarding IC" are used throughout this document to designate a point of contact for advice and interpretation of grant requirements and to establish the focal point for requesting necessary prior approvals or changes in the terms and conditions of award., the HHS Office of Inspector General (OIG), and the pass-through entity (if applicable) whenever, in connection with the Federal award (including any activities or subawards), it has credible evidence of the commission of a violation of Federal criminal law involving fraud, conflict of interest, bribery, or gratuity violations found in Title 18 of the United States Code or a violation of the civil False Claims Act (31 U.S.C. 3729–3733). Disclosures must be sent in writing to the NIH awarding IC The NIH organizational component responsible for a particular grant program or set of activities. The terms "NIH IC," or "awarding IC" are used throughout this document to designate a point of contact for advice and interpretation of grant requirements and to establish the focal point for requesting necessary prior approvals or changes in the terms and conditions of award. and to the HHS OIG at the following address:

NIH CGMO listed on the NoA Notice of Award: The official, legally binding document, signed (or the electronic equivalent of signature) by a Grants Management Officer that: (1) notifies the recipient of the award of a grant; (2) contains or references all the terms and conditions of the grant and Federal funding limits and obligations; and, (3) provides the documentary basis for recording the obligation of Federal funds in the NIH accounting system. for the IC The NIH organizational component responsible for a particular grant program or set of activities. The terms "NIH IC," or "awarding IC" are used throughout this document to designate a point of contact for advice and interpretation of grant requirements and to establish the focal point for requesting necessary prior approvals or changes in the terms and conditions of award. that funded the grant (See Part III: Points of Contact 20 INSTITUTES AND CENTERS)

AND

Office of Counsel to the Inspector General

Office of Inspector General

U.S. Department of Health and Human Services

Grant Self-Disclosure

330 Independence Avenue, SW, Cohen Building

Room 5527

Washington, DC 20201

URL: https://oig.hhs.gov/compliance/self-disclosure-info/hhs-oig-grant-self-disclosure-program/

Email: [email protected]

Failure to make required disclosures can result in any of the remedies described in 2 CFR Part 200.339. Remedies for noncompliance and Administrative Requirements – Enforcement Actions, including suspension or debarment (See 2 CFR Part 180 and 376, 31 U.S.C.3321 and Public Policy Requirements and Objectives— Debarment and Suspension), as necessary and appropriate.